Wedbush Securities Inc. Boosts Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Wedbush Securities Inc. grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,302 shares of the medical research company’s stock after acquiring an additional 34 shares during the period. Wedbush Securities Inc.’s holdings in Thermo Fisher Scientific were worth $2,379,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of TMO. International Assets Investment Management LLC raised its position in shares of Thermo Fisher Scientific by 17.0% during the 4th quarter. International Assets Investment Management LLC now owns 1,902 shares of the medical research company’s stock worth $1,010,000 after purchasing an additional 276 shares during the last quarter. Accretive Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 8.1% during the fourth quarter. Accretive Wealth Partners LLC now owns 640 shares of the medical research company’s stock valued at $340,000 after acquiring an additional 48 shares during the last quarter. Aveo Capital Partners LLC lifted its position in shares of Thermo Fisher Scientific by 9.7% in the fourth quarter. Aveo Capital Partners LLC now owns 816 shares of the medical research company’s stock valued at $433,000 after acquiring an additional 72 shares in the last quarter. Gryphon Financial Partners LLC increased its position in shares of Thermo Fisher Scientific by 8.5% during the fourth quarter. Gryphon Financial Partners LLC now owns 1,484 shares of the medical research company’s stock worth $794,000 after purchasing an additional 116 shares in the last quarter. Finally, Jump Financial LLC purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at $1,399,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 6,300 shares of the stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $602.09, for a total transaction of $3,793,167.00. Following the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $74,548,375.44. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 23,084 shares of company stock worth $14,094,292. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Trading Up 1.5 %

NYSE:TMO opened at $620.42 on Tuesday. The stock has a fifty day moving average price of $585.64 and a 200 day moving average price of $578.80. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $622.30. The firm has a market cap of $237.00 billion, a PE ratio of 39.80, a price-to-earnings-growth ratio of 2.84 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. The company had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The firm’s quarterly revenue was down 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.15 earnings per share. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be paid a $0.39 dividend. The ex-dividend date of this dividend is Friday, September 13th. This represents a $1.56 annualized dividend and a yield of 0.25%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Analysts Set New Price Targets

TMO has been the topic of a number of recent research reports. Royal Bank of Canada boosted their price target on shares of Thermo Fisher Scientific from $660.00 to $664.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Stifel Nicolaus boosted their price objective on Thermo Fisher Scientific from $600.00 to $615.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Raymond James lifted their price target on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Evercore ISI decreased their target price on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Finally, Barclays cut their price target on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating for the company in a report on Friday, June 28th. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $630.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.